Literature DB >> 1557187

Symptomatic and prophylactic treatment of migraine and tension-type headache.

E A Schulman1, S D Silberstein.   

Abstract

Pharmacotherapy is the mainstay for patients with persistent headaches. When simple analgesics can no longer be used, combination analgesics are prescribed. Symptomatic medications also include antiemetics, ergot derivatives, corticosteroids, neuroleptics, and narcotics. Nonsteroidal anti-inflammatory drugs are commonly used both symptomatically and prophylactically, and are the treatment of choice for menstrual migraine. Exertional migraine, benign orgasmic cephalalgia, chronic paroxysmal hemicrania, cough headache, and "ice-pick" headache are treated with indomethacin. Ergotamine tartrate is often recommended when simple or combination analgesics do not relieve headaches. Dihydroergotamine (DHE) is effective for treating intractable headache; because it has fewer side effects than ergotamine, it is tolerated by patients unable to tolerate other ergotamine preparations. DHE is administered IM and, for occasional use, patients can be taught self-injection. Repetitive IV DHE therapy for chronic severe headaches requires hospitalization; most patients become headache-free within 3 days. Patients who refuse hospitalization, do not respond to the drug, or are not suitable candidates for DHE therapy may receive a short course of a corticosteroid, a neuroleptic or, rarely, a narcotic. For frequent headaches, prophylactic treatment usually begins with a tricyclic antidepressant or a beta blocker.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1557187

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  2 in total

Review 1.  Recent advances in the acute management of migraine and cluster headaches.

Authors:  K L Kumar
Journal:  J Gen Intern Med       Date:  1994-06       Impact factor: 5.128

2.  Precipitating and relieving factors of migraine versus tension type headache.

Authors:  Badrul Haque; Kazi Mohibur Rahman; Azharul Hoque; A T M Hasibul Hasan; Rajib Nayan Chowdhury; Sharif Uddin Khan; Mondal Badrul Alam; Mansur Habib; Quazi Deen Mohammad
Journal:  BMC Neurol       Date:  2012-08-25       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.